Urogen Pharma (NASDAQ:URGN – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a report issued on Friday,Benzinga reports. Wall Street Zen raised Urogen Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, September 13th. Get Urogen Pharma alerts:View Our Latest Report on Urogen PharmaUrogen Pharma Stock PerformanceShares of Urogen Pharma stock opened at $17.40 on Friday. Also, General Counsel Jason Drew Smith sold 7,522 shares of Urogen Pharma stock in a transaction dated Monday, July 28th. Read MoreReceive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.